Inclusive
and affordable
healthcareReport 2
Inclusive and affordable healthcare
COVID-19 won’t be the last pandemic in our lifetimes. We’ll likely see more andmore epidemics stemming from the impact of human activity on the environment.
Think deforestation, thawing permafrost, and our rising resistance to antibiotics.
In addition, the WHO anticipates a demographic shift that will put more than 22%of our population (1) in the over-60 age bracket by 2050. What will that mean?
An inevitable increase in demand for remote diagnostics and care is sure to accelerate
the convergence of digitization and healthcare.
Not insignificantly, it was deep tech startups BioNTech and Moderna that developed a vaccine to fight COVID-19 in less than a year. Heavily influenced by the ongoing situation and the futuristic advances made in medicine, this year’s deep techtrends in healthcare involve the digitization of health tech (digital patient twins),
regenerative medicine, next generation diagnostics, and advanced therapeutics.
2.1 Digital patient twins
Building on the momentum of digitization of healthcare, digital twin technology,
a new concept of digital replication that generates virtual models of objects or
systems, is paving the way for personalized medicine. Using real-time data feeds,
digital biomarkers, and machine learning, digital patients’ twin solutions dramatically improve the way patients are diagnosed and treated, leading the charge
towards an interconnected ecosystem of care.
2.2 Regenerative medicine
Development of regenerative approaches to heal a range of injuries, including
post-operative wounds, is growing by more than 11% annually and is set to reach$57.08 billion by 2027. Imagine a world where normal breast shape can be restored post-mastectomy, or where biodegradable steel implants are used to heal bone
fractures. Thanks to advances made in stem cell technology and new materials,
regenerative medicine has entered a new era.
2.3 Next generation diagnostics
The recent pandemic has emphasized the vital role played by polymerase chain
reactions (PCR), next-generation sequencing (NGS), and serology tests, with the PCR
segment claiming the highest growth rate in 2020. Technologies like CRISPR and
LAMP are introducing the efficiency and reliability of genomics testing to remotediagnostics. Advances made in molecular biology, sensor technology, AI, and medical
imaging and their convergence has taken diagnostics out of sophisticated labs toprovide point of care diagnosis within minutes and often directly accessible to the patient. Few, if any, will miss the “hours if not days” medical tests requiring rigorous
clinical laboratory settings and skilled technicians to perform them.
2.4 Novel molecular therapeutics in the post-COVID-19 era
If digital patient twins and molecular diagnostics are the first step in the journey
towards personalized treatments, therapies and enabling therapeutics are thesecond. Finding cures for diseases like cancer, genetic disorders, and the dreaded
resistance to antibiotics, which have rankled hospitals around the world, seems
like an endless tunnel. Molecular therapeutics powered by advances in genomics,
proteomics, and cellular biology may well be the light at the end.
2

Inclusive and affordable healthcare – Hello Tomorrow | Boston Consulting GroupInclusive
and affordable
healthcare

Why it matters
While deep tech and digitization in healthcare will not replace healthcare professionals(HCPs), they will certainly enhance the healthcare experience for both patients and HCPs.
Advances with deep tech and digitization can reduce HCP overload by assisting themwith early and accurate diagnoses of health problems, generate optimum treatment plans,
and facilitate latest interventions towards improved patient outcomes. The confluence of
medicine and technology is revolutionizing healthcare by addressing some of its most persistent challenges such as rising treatment and pharmaceutical costs, HCP shortages, andepidemic preparedness.
Due in part to COVID-19 and the aforementioned challenges, the healthcare market isprojected to reach $10 trillion by 2022 (3). In 2020, global AI alone generated $8.23 billion
for the healthcare industry and is estimated to reach $19.4 billion by 2030, implying a CAGR
of 38.1% from 2021 until then (4).

An ecosystem game — Why should we be team players?
Moderna and BioNtech showed the world that startups, and not big pharmaceutical companies, were able to bring mRNA vaccine technology up to speed to fight COVID-19. Bycollaborating with corporations, startups were able to pull off the incredible feat of developing, producing, certifying, and distributing vaccines — with half of the world’s population
getting at least one shot — in less than a year. This rapid scaling up was made possible by
the evolution of platform technologies, and by the intense collaborations formed within
the ecosystem. Decades of research were needed to build and perfect the LNPs, or Lipid
Nanoparticles, that were used to deliver the mRNA to the cells, the covid virus genome wassequenced by researchers in another part of the world, while the platform infrastructure
to mass produce the vaccines came from corporates like Pfizer and Lonza. Each of thesecomponents was imperative for the eventual vaccine production.
The multiple partnerships formed in the ecosystem are the key success factor for making
the vaccine production and distribution possible on an accelerated time scale. Collaborative approaches in the ecosystem are the key to large-scale industry disruptions. Companies
must capitalize on these approaches to answer current and future health care challenges
successfully. Managing the ecosystem’s complexity and diversity will remain challenging,but successfully navigating them might determine the next disruptive healthcare product/
service to appear in the market.

3

Inclusive and affordable healthcare – Hello Tomorrow | Boston Consulting GroupOverview of trends
This year, deep tech pioneers proved that solutions they developed can truly help solve thehealth challenges of this decade by helping to build more resilient, inclusive, and affordable
healthcare.
Keys to this achievement are the digital capabilities these solutions employ to create digitalpatient twins at scale, increased precision in the fine-tuning of treatments, and boosting
progress in drug discovery (see page 6). Some of these startups have taken inspirationfrom nature to design implants that can enhance tissue growth and repair, prompting natural regeneration (see page 12). At the same time, plug-and-play solutions have facilitatedremote and point-of-care diagnostics, and novel molecular therapeutics could provide thesolution to problems like antibiotic resistance (see page 20).

What’s next to watch?
A review of over 218 deep tech pioneers selected this year (133 in Digital Healthcare andMedical Devices, and 85 in Medical Biotech) revealed multiple areas of interest. However,digitalization of healthcare leading to its delocalization and democratization, is a key upcoming trend that has taken the market by storm.
Virtonomy » Medical device
testing can take up to 10
years and more, resulting
in high development costs.
Virtonomy’s v-Patients are
3D/4D anatomy models
created using high-resolution
CT scans that offer virtual
medical device testing, datadriven clinical trials on digital
twins, decreased animal andhuman trials, and accelerated
time to market.

Old world: medical device development

Concept
design

Bench
tests

Prototyping

Animaltests

Cadaver

Animaltrials1000x more expensive iteration loop

New world: medical device development with virtonomy

Concept
designVisual Patients& Simulation

Prototyping

1x expensive
iteration loop

4

Inclusive and affordable healthcare – Hello Tomorrow | Boston Consulting Group

Virtual Testing& Animal Trial

In Silico Trial& Clinical Trial

ClinicaltrialsTrends’ expected time to market (5)2030

page 20-21

Novel molecular therapeutics in the post-COVID-19 era
Chain Biotech » Microbiome therapeutics company developing
oral immuno-therapies, i.e. oral vaccines
Trobix Bio » Phage-based antibiotic sensitizing solution thatcreates a selection pressure to reverse antibiotic resistance.
SideROS » Ironomycin is a chemical molecule that disturbs ironhomeostasis in persistent cancer cells, and provokes cancer cell death.

2028

page 12-13

page 16-17

Regenerative
medicine

Next generation
diagnostics

Healshape »Breast bioprosthesis.

D-NOME » Creatingplug-and-play solutions
to the DNA diagnostic
methods without complex instruments, thereby bringing Point ofCare (POC) affordable
solutions to the market.

Medjeduse » Patented
degradable biomaterial
for recovery from spine
injury.

2026

2024

Ochre Bio »Pre-treatment of suboptimal donor livers
and treatmentof non-symptomatic
cirrhosis by using
deep phenotyping for
drug development.

Medical Magnesium »Bioabsorbable orthopedic implants madeof proprietary magnesium alloy.

page 8-9

Digital patient twins
RTsafe » 3D printed, individual patient-specificmodel of human head and brain to foresee cancer
radiation treatment impacts.
iLoF » Cloud-based library of diseases biomarkers
and biological profiles built from unique patient
optical fingerprints, using AI and photonics.

2022

5

IDUN Technologies » Translating brain waves into
emotional and cognitive insights, developing a kit
for products or services enhancements throughneurofeedback.

Inclusive and affordable healthcare – Hello Tomorrow | Boston Consulting Group

DeepSpin » Portable
MRI created using an
AI-powered intuitive interface and system design to reduce the weightand size of the MRI
while keeping the image
quality comparable andlowering the costs.
Pear Bio » Organ-ona-chip technology withalgorithms that measure the impact of different treatment options
on stopping cancer in
its tracks i.e. personalized treatments for cancer patients.
Klavant Gmbh »IDA — Intraoperative
Digital Aortography reduces the need for reoperations during aortic
valve reconstruction.

2.1 Digital patient twins
Digital twin technology, a new concept of digital replication that generates virtual
models of objects (like engines or even people) or systems, has already disrupted
the aeronautics and construction industries. Building on this momentum, it is
now paving the way toward more efficient, less intrusive, and more personalized
medicine. How? By empowering patients, doctors, and healthcare organizations
to better understand and manage health, test, and predict treatment and lifestyle
habit outcomes. Using new captors, real-time data feeds, and machine learning,
digital patients’ twin solutions produce models that offer a more accurate visionof what healthcare professionals are dealing with. By drawing individual data
points from a variety of unique and secure biomarkers, they are helping to build
a more interconnected ecosystem of care.

2.1.1

Why does it matter now?
Making use of digital twins could dramatically improve the way patients are diagnosed
and treated. Digital twins are non-invasive in nature, cater to personalized medicine approaches, and would be instrumental in curbing costs in clinical trials and medical device
testing. They would also align with future public healthcare schemes aimed at increasing
value/performance-based medicine. Value/performance-based medicine refers to a system
where drugs are reimbursed based on their performance and health providers arepaid based on the patient's health outcomes.

2.1.2

Applications and market potential
Digital patient twins operate at the crossroads of large, dynamic markets. These include
personalized medicine, which is expected to reach $751 billion by 2027, and niche markets
like global digital biomarkers, which is expected to grow at 30.6% CAGR reaching $22.54
billion in the next decade. There are two factors driving
this steady market growth: an increase in the demandfor personalized medicine and the effort to optimize
early-stage drug development costs by pharmaceuticalcompanies. Startups have already begun developing
practical applications to this revolutionary technology.
This year, deep tech startups produced digital organs
that simulate patient reactions to treatments, and helping practitioners to fine-tune personalized medicine.
Cloud-based digital biomarker solutions for optimizing
patient data access and evolved technologies are helping us better understand our emotions.

2.1.3

Key roadblocks to overcome
As promising as its start may be, digital patient twin technology faces multiple hurdles on
its way to becoming a solution widely embraced by the healthcare domain. The most significant of these are fragmented, ever-evolving patient data, a lack of digital twin development
models in healthcare, and privacy and security concerns
in established healthcare practices (GDPR, HIPAA, clinical
trials, and medical device testing) — not to mention its inherently high development costs.
To fully unleash this trend’s economic potential, industry
policy makers and researchers will need to make a collective and collaborative effort to develop and mobilize thehealthcare ecosystem around digital twin technology, ensuring its rapid adoption.

7

Digital patient twins – Hello Tomorrow | Boston Consulting Group“Digital twins are non-invasivein nature, cater to personalized
medicine approaches, and would
be instrumental in curbing
costs in clinical trials and medical
device testing”

2.1.4

Use cases
RTsafe » Brain cancer radiotherapy is stillrisky and could cause severe side effects(blindness, paralysis, early death) or evenprove inefficient as a treatment. In a world
first, RTsafe has developed, patented, andcommercialized a process/device to form
an anatomically accurate 3D-printed replicaof the patient’s head that can perfectly
mimic the interaction with radiation. Thismeans medical teams can simulate a planned
treatment before administering the latter tothe real patient, establishing radiological andgeometrical accuracy of the delivery to reduce any unforeseen risks.
iLof » For many complex and heterogeneous
diseases like Alzheimer’s, the idea that one
medication works equally for everyone no longer holds water. iLof develops unique opticalfingerprints for patients using AI and photonics
to build a cloud-based library of disease biomarkers and biological profiles. Efficient, portable, and inexpensive for the industry,
comfortable patient screening is made possible
by “fingerprints” collected from nano-scale
structures in blood and bodily fluids (e.g.
serum, plasma). As a result, trials can be optimized and millions of euros saved by eliminating costly procedures like PET scans andlumbar punctures on patients that will be
excluded from trials.

8

Digital patient twins – Hello Tomorrow | Boston Consulting GroupIDUN Technologies AG » A better understanding of our brain signals is key in treating certain diseases like epilepsy and in more general applications like sleep management. IDUN
Technologies AG translates brain waves into
cognitive and actionable insights to produce
a kit for electronic manufacturers, pharmacompanies, and automotive or content providers wishing to enhance their products andservices with neurofeedback. The productenables new biomarker exploration (depression, epilepsy, and more) that could dramatically reduce the time and cost needed
to correctly diagnose and prescribe the best
medical treatment, making EEG available
to the mass market in a non-obtrusive way.

2.1.5

What our startups need
Collaboration opportunities and constraints based on our deep tech pioneers' insights.
Experiment
1

2

Exploration

Develop3

4

Experimental,
proof of concept

Scale

5

6

7

Functional
proof ofconcept

Minimum
viable product9

Industrialization

Commercialization» Giving access to Lab
and testing facilities.

» Accelerating productdistribution.

» Financing investigative
studies.

» Giving access to specificcustomer bases.

» Leveraging national orinternational public-private
corporate and startups
consortium projects to facilitate access to larger pharma-lead clinical trials.

98

Digital patient twins – Hello Tomorrow | Boston Consulting Group

2.2 Regenerative Medicine
Regenerative medicine has inspired humankind’s imagination since the mythof Prometheus and his regenerating liver. Only recently has the myth become
reality. The term “regenerative medicine” was first used by Leland Kaiser in his
1992 paper listing key technologies set to revolutionize the way we heal andthe future of hospital processes. That the future is now. Combining knowledge
from the fields of tissue engineering (TE), cell transplantation, stem cell biology,
biomechanical prosthetics, nanotechnology, and biochemistry, regenerative
medicine is now able to restore or regenerate functioning tissue, cells, and organs.

2.2.1

Why does it matter now?
Regenerative medicine refers to finding cures for previously untreatable diseases and injuries, often by restoring the structure and function of damaged tissues and organs. Patientsand healthcare industry actors alike can now avoid additional patient suffering and stigma
brought on by removal surgeries, thanks to regenerative medicine. The technology canbuild on bodies’ healing capabilities, giving rise to entirely new markets and treatments.

2.2.2 Applications and market potential
Absorbable implants
The most outstanding applications from this year’s Hello Tomorrow
Global Challenge explore the use of regenerative approaches in healing a range of injuries, including post-operative wounds. Some ofthese include post-mastectomy breast bioprostheses that promotenatural tissue growth and are absorbed by the body to restore anormal breast shape, or the use of natural materials like silk for bonereconstruction or controlled magnesium absorption, and biodegradable steel implants to heal bone fractures. As a market, regenerative medicine is growing more than 11% annually and is set to reach$57.08 billion by 2027 (6), with oncology claiming the lion’s share ofestimated revenue.

2.2.3 Key roadblocks to overcome
Two key roadblocks stand in the way of regenerative medicine becoming a mainstream treatment: high development
and final costs, and the stringent regulatory approvals it currently requires. Existing cellular and tissue regenerative treatments can cost anywhere from $100,000 to millions.
As it stands, these high costs can be mitigated by decentralized production of cells, better reimbursement schemes,
and improved bioengineering to lower the cost of cultivating
and testing the cells. The regulatory and compliance certification process must be accelerated, a goal only achievablethrough expertise and knowledge sharing (most of theseapproaches being for Class 3 devices) of device design andits decentralized manufacturing.

11

Regenerative Medicine – Hello Tomorrow | Boston Consulting Group“Regenerative medicine
can build on bodies’ healing
capabilities, giving rise toentirely new markets andtreatments”

2.2.4 Use cases
Healshape » Of the 2 million women diagnosed with breast cancer worldwide in
2018, 40% got mastectomies, but only 30%
opted for breast reconstruction. Healshapehas developed a breast bioprosthesis, URshape, that restores shape and volume upon
implantation. UR-shape implantation is donein tandem with a transfer of the patient’s own
cells. Over time, the bioprosthesis is graduallyabsorbed and the patient’s tissue is restored
as normal.

Medjeduse » According to the WHO, between
250,000 and 500,000 people suffer spinal
injuries every year, and most are men between
16 and 30. Medjeduse has developed a patented degradable biomaterial (quasi-liquidhydrogel) that, when injected into a spinal
cord lesion resulting from a traumatic shock,preserves and restores functional endogenous
spinal tissue. The process also reconnects neuronal fibers and the surrounding cellular environment that would otherwise degenerate,causing sensory-motor interruption.

12

Regenerative Medicine – Hello Tomorrow | Boston Consulting GroupMedical Magnesium » Each year sees around
180 million bone fractures. In a smarter approach to healing them, Medical Magnesium
gmbh has developed bioabsorbable orthopedic implants made of magnesium that use
a proprietary magnesium alloy combinedwith a ceramic plasma-electrolytic oxidation
coating (PEO). With it, the startup can pilot
the metal’s degradation — the crucial factor
in bioabsorbable implant technology. As aresult, the implant remains stable until the
broken bone regains mechanical integrity.
Once this is achieved, the implant degrades
physiologically as new bone tissue forms.

2.2.5 What our startups need
Collaboration opportunities and constraints based on our deep tech pioneers' insights.
Experiment
1

2

Exploration

Develop3

4

Experimental,
proof of concept

Scale

5

6

7

Functional
proof ofconcept

Minimum
viable product89Industrialization

Commercialization» Bringing prior knowledge
to the preclinical stage ofcertification.
» Clinical evidence for eachstakeholder involved, be
it customers (surgeons),
payers (healthcare system,
insurance companies)
or end-users (patients).
» Connecting to experienced
entrepreneurs or businesspeople experienced in scaling healthtech and medtech
companies.
» Helping startups build
a strong network of KOLs
(surgeons).
» Co-publishing clinicaldata with KOLs to illustrate
the cost-effectiveness andadded value.
» Growing market sharethrough collaborative deviceroll-outs.

13

Regenerative Medicine – Hello Tomorrow | Boston Consulting Group

2.3 Next generation
diagnostics
Next generation diagnostics refers to a collection of the latest molecular biology and imaging techniques as applied to different phases of medical testing,from detection to diagnosis, prognosis, and therapy response monitoring. At
the end of the last decade, next generation diagnostics already included techniques like genomic and proteomic biomarkers, Next-Gen Sequencing, CRISPR
and analysis of other biomolecules characteristic of a disease. Recently, healthcare adjustments in response to the COVID-19 pandemic has brought two additional techniques to light: remote care and rapid POC (point of care) diagnostics.

14

Next generation diagnostics – Hello Tomorrow | Boston Consulting Group

2.3.1

Why does it matter now?
On the journey towards personalized treatments, diagnostics is the first step. Being able
to rapidly detect a disease will give medical practitioners the time they need to make theright clinical decisions. Additionally, the ability to monitor a given therapy throughout its
duration will lead to more efficient and effective treatments through targeted therapeutics.
Lastly, analyses based on the detection of cell phenotypes and nucleic acids — both DNA
and RNA — enable much faster, more sensitive, and more precise identification of viruses,bacteria, and parasites than do traditional diagnostics.

2.3.2 Applications and market potential
Molecular tests
The recent pandemic has highlighted the practical application of thepolymerase chain reactions (PCR), next-generation sequencing (NGS), andserology tests, with the PCR segment claiming the highest growth rate in2020 (7). In fact, the global molecular diagnostics market (8) is expected togo from $17.8 billion in 2021 to $31.8 billion by 2026. This large scale growthis owed largely to the use of PCR and qRTPCR in genomics and proteomics,
PCR automation and repeat purchases of reagents and kits.

AI based diagnostics
The global market for AI in medical imaging is expected to
hit $20.11 billion by 2031 (9). In parallel, the global clinical decision support system market is on track to go from an estimated $1.2 billion as of 2020 to $1.8 billion by 2025. (10)2.3.3 Key roadblocks to overcome
Traditional diagnostics mean heavy instrumentation, laboratory testing, longer detection
time periods, and hefty price tags. Additionally, monitoring the response to an ongoing
therapy (companion diagnostics) and discovery of new biomarkers remain incredibly expensive for now. AI supported medical imaging solutions and clinical-decision making are
yet to be widely adopted by clinicians, patients, and reimbursement schemes. There is aneed for democratization of patient data while associated policies need to be redefined toaccelerate the time to market for innovations based on healthcare datasets.

15

Next generation diagnostics – Hello Tomorrow | Boston Consulting Group“There is a need for
democratization of patient data
while associated policies need
to be redefined to accelerate thetime to market for innovations
based on healthcare datasets.”

1.3.4 Use cases
D-NOME » PCR and qPCR technologies
require specific multi-step temperature
cycling instruments. D-NOME is introducing
plug-and-play solutions to the DNA diagnostics game. Their innovative technology
enables cell-free DNA/RNA amplification at
37°C with no complex instruments needed,bringing solutions that are both Point of Care
(POC) and affordable to market.

DeepSpin » In 2020 (11), the MRI (magnetic resonance imaging market) was valued
at $5.3 billion and is expected to achieve a
6.0% compound annual growth rate (CAGR)
between 2021 and 2028. However, MRIs arelarge machines that weigh several tons andcome at a high price. DeepSpin uses an
AI-powered system design to reduce themachine’s weight while maintaining comparable image quality and curbing costs.

16

Next generation diagnostics – Hello Tomorrow | Boston Consulting GroupPear Bio » Around 10 million people diedof cancer in 2020. Even now, available cancer
treatments can produce different resultsfrom one patient to the next, which is why
Pear Bio is developing personalized cancer
treatments. The startup monitors cancer progression in patient-derived tumor samples
against potential treatment options. Theirorgan-on-a-chip technology recreates core
parts of the human tumor microenvironment
for precision testing. Additionally, their computer-vision algorithms measure the efficacy
of each treatment in stopping the cancer andremoving the tumor.
Klavant Gmbh » Intelligent, or AI-powered,
medical imaging has secured its role in Oncology, COVID-19 diagnosis, and even intraoperative care. Klavant Gmbh’s IDA-Intraoperative
Digital Aortography limits the need for reoperations during aortic valve reconstruction— a major advance considering that undetected leakages during intraoperative procedures
can currently result in cumulative mortality
and morbidity rates of up to 13%.

2.3.5 What our startups need
Collaboration opportunities and constraints based on our deep tech pioneers' insights.
Experiment
1

2

Exploration

Develop3

4

Experimental,
proof of concept

Scale

5

6

7

Functional
proof ofconcept

Minimum
viable product89Industrialization

Commercialization» Providing production
infrastructure.
» Creating specific supply
chains.
» Introduction to networks
for financial market expansion.
» Using the existing regulatory
networks to gain faster approvals thereby decreasing the
product to market timeline.

17

Next generation diagnostics – Hello Tomorrow | Boston Consulting Group

2.4 Novel molecular therapeutics
in the post-COVID-19 era
If molecular diagnostics is the first step in the journey towards personalized
treatments, therapies and enabling therapeutics are the second. Ongoingadvances in genomics, proteomics, and cellular biology are taking moleculartherapeutics to another level. Due to these advances, we have progressed toa point where mRNA can be leveraged therapeutically in a vaccine, with widescale application, as witnessed during the COVID-19 pandemic. This progressoffers a new perspective into mRNA, DNA and other biomolecules as therapeutics, ushering a new era for molecular therapeutics.

18

Novel molecular therapeutics in the post-Covid era – Hello Tomorrow | Boston Consulting Group

2.4.1

Why does it matter now?
Finding cures for diseases like cancer, genetic disorders, and the dreaded resistance toantibiotics that have rankled hospitals around the world seems like an endless tunnel.
But advances in molecular therapeutics are now offering a bright end in sight, giving us
the means necessary to successfully respond to both the future pandemic scenarios andongoing healthcare challenges.

2.4.2 Applications and market potential
In 2020, the global antibiotics market was valued at $40.7 billion dollars and is expected to
grow to $57.99 billion by 2028 (12). In parallel, the global antibiotic resistance market was valued at $7.81 billion in 2017 (13), and is showing no signs of slowing down. The 5 publicly-listedcompanies developing mRNA had a combined market cap of $15 billion in 2020, which thengrew to around $300 billion by August 2021 (14). Comparatively, the global DNA vaccine market is only expected to grow from its $3.1 billion 2021 size to $11.5 billion by 2026 (15).

2.4.3 Key roadblocks to overcome
The advancement of molecular therapeutics faces multiple hurdles, not least of which arehigh research and development costs. Added to this are a hesitation to adopt amongst
HCPs and the public alike, a lack of clinical trial designs that can determine the efficacy andduration of therapy effectiveness in selected populations, and a need for new supply chains(ex. cold storage and transport for mRNA vaccines).

19

Novel molecular therapeutics in the post-Covid era – Hello Tomorrow | Boston Consulting Group“Advances in moleculartherapeutics are giving us
the means necessary to
successfully respond to
future pandemic scenarios”

2.4.4 Use cases
Chain Biotech » The discovery of vaccines
counts among the medical breakthroughs thathave doubled average human life expectancy.
The need for novel vaccines is more important
than ever, given the recent pandemic. No
surprise then that the novel vaccine delivery
system market is expected to top $14.4 billion
by 2030. Chain Biotech is a microbiome therapeutics company developing oral immunotherapies using a precision-engineeredbacterium, Clostridium, to deliver therapeutic
payloads to the lower gastrointestinal tract(GI). The payoff? Immunization, in the formof oral microbiome vaccines.
Trobix Bio » Each year, antibiotic resistanceis responsible for an estimated 700,000
deaths — a number expected to hit 10 million
by 2050 (16). In response to this growing issue,
Trobix Bio combines CRISPR and synthetic
biology to engineer phages equipped with
their ActiSenseTM technology to deliver DNA
payloads targeting bacteria. This, in turn,creates selective pressure that reverses antibiotic resistance, thereby sustaining an antibiotic-sensitive environment.

20

Novel molecular therapeutics in the post-Covid era – Hello Tomorrow | Boston Consulting Group

SideROS » For cancer patients, recurrence isstill one of the leading causes of death andlifestyle deterioration. The global chemotherapy market is projected to reach a market
value (17) of $74.3 billion by 2027. SideROS hasdeveloped a molecule, Ironomycin, capableof accumulating in persistent cancer cells resulting in the disruption of iron homeostasis,
which in turn promotes cancer cell death.

Ochre Bio » Each year, liver disease is behindapproximately 2 million deaths (18). But whileliver transplants are the second most common organ transplants, less than 10% of global transplant needs are actually being met.
Ochre Bio is bridging the gap between the
demand for donor livers and suitable donorlivers by pretreating suboptimal donor livers
and treating asymptomatic cirrhosis using
Deep phenotyping for drug development.
Their approach combines genetics, advanced
tissue imaging, cellular genomics, and machine learning to disease and gene systems
at the tissue level.

2.4.5 What our startups need
Collaboration opportunities and constraints based on our deep tech pioneers' insights.
Experiment
1

2

Exploration

Develop3

4

Experimental,
proof of concept

Scale

5

6

7

Functional
proof ofconcept

Minimum
viable product89Industrialization

Commercialization» Investing in long-term
ventures and fundamental
research.
» Providing infrastructure andcreating specific supply chains.
» Providing specificproduction facilities.
» Clinical trial recruitments
and management.
» Using the existing regulatory
networks to gain faster approvals thereby decreasing the
product-to-market timeline.

21

Novel molecular therapeutics in the post-Covid era – Hello Tomorrow | Boston Consulting GroupSources
1 - who.int
2 - marketsandmarkets.com
3 - businesswire.com
4 - globenewswire.com
5 - Hello Tomorrow Global competition 2021
6 - prnewswire.com
7 - marketsandmarkets.com
8 - marketsandmarkets.com
9 - transparencymarketresearch.com
10 - marketsandmarkets.com
11 - grandviewresearch.com
12 - grandviewresearch.com
13 - grandviewresearch.com
14 - nature.com
15 - businesswire.com
16 - who.int
17 - globenewswire.com
18 - pubmed.ncbi.nlm.nih.gov

Authors
Arnaud de la Tour CEO Hello Tomorrow
Saurabh Tak Deep Tech Lead Hello Tomorrow
Nicolas Goeldel Project Leader BCG
Malvika Verma Project Leader BCG
Anne-Douce Coulin Manager Deep Tech Mission BCG

Hello Tomorrow is accelerating radical solutions to improve human and planetary health, leveraging the powerof deep tech ventures. Its flagship startup competition, the Hello Tomorrow Global Challenge, received morethan 25,000 applications from 132 countries. Thousands of corporates and VCs attend Hello Tomorrow events
every year. Leveraging this international network and knowledge of deep tech trends, Hello Tomorrow partners withprivate and public organizations to help them identify new opportunities, and build new ventures to seize them.

Boston Consulting Group (BCG) partners with leaders in business and society to tackle their most important
challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was
founded in 1963. Today, we help clients with total transformation – inspiring complex change, enabling organizations to grow, building competitive advantage, and driving bottom-line impact.
To succeed, organizations must blend digital and human capabilities. Our diverse, global teams bring deep industry and functional expertise and a range of perspectives to spark change. BCG delivers solutions throughleading-edge management consulting along with technology and design, corporate and digital ventures – andbusiness purpose. We work in a uniquely collaborative model across the firm and throughout all levels of theclient organization, generating results that allow our clients to thrive.
22

Inclusive and affordable healthcare – Hello Tomorrow | Boston Consulting Group